DMC Recommends Biophytis Continue Sarconeos COVID-19 Study

The Data Monitoring Committee (DMC) has recommended Biophytis SA BPTS to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after reviewing of safety data.
The COVA clinical program is assessing Sarconeos (BIO101) in patients aged 45 and older hospitalized with severe respiratory manifestations of COVID-19.
The independent DMC meeting was dedicated to analyzing safety data from the first 155 randomized patients.
The DMC will review the efficacy data of the 155 patients in Q3 2021 as part of the second Interim analysis to recommend futility and final sample size.
The Company is progressing to complete the recruitment of the 310 patients and report top-line results in Q4 of 2021.
Price Action: BPTS shares closed 1.27% higher at $8.54 on Friday.
Related content: Benzinga's Full FDA Calendar.